Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Yuanda Wan"'
Autor:
Yuanda Wan, Liren Li, Ruilin Chen, Jiajia Han, Qiyun Lei, Zhipeng Chen, Xiaodong Tang, Wenyu Wu, Shuwen Liu, Xingang Yao
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 3, Pp 1362-1379 (2024)
Extracellular vesicles (EVs) have recently emerged as a promising delivery platform for CRISPR/Cas9 ribonucleoproteins (RNPs), owing to their ability to minimize off-target effects and immune responses. However, enhancements are required to boost the
Externí odkaz:
https://doaj.org/article/85431f5a293d4deb8a987de7fa52e85b
Autor:
Wenyu Wu, Ruilin Chen, Yuanda Wan, Liren Li, Jiajia Han, Qiyun Lei, Zhipeng Chen, Shuwen Liu, Xingang Yao
Publikováno v:
Molecules, Vol 27, Iss 23, p 8583 (2022)
Dengue fever is the most common mosquito-borne viral disease and is caused by the dengue virus (DENV). There is still a lack of efficient drugs against DENV infection, so it is urgent to develop new inhibitors for future clinical use. Our previous re
Externí odkaz:
https://doaj.org/article/f4dd6e6c1e56450591cd2bc7ae014a66
Publikováno v:
Pharmacology. 107:584-600
Introduction: Pancreatic β-cell dysfunction is largely regulated by TXNIP accumulation, we have previously disclosed the role of PKA in TXNIP degradation during β-cell dysfunction. However, whether other kinases (PKCs) still regulate TXNIP is uncle
Autor:
Liren Li, Jiawen Zhang, Xiaodong Tang, Xiaoguang Chen, Yihong Wan, Xingang Yao, Wenyu Wu, Yuanda Wan, Shuwen Liu
Publikováno v:
European journal of pharmacology. 907
Dengue fever is a common arbovirus disease, which has been spread to the entire tropical world. At present, effective drugs for the treatment of dengue fever have not yet appeared, and the dengue vaccines studied in various countries have also experi
Autor:
Daoyuan Xie, Yaomei Tian, Die Hu, Yuanda Wang, Yuling Yang, Bailing Zhou, Rui Zhang, Zhixiang Ren, Mohan Liu, Jie Xu, Chunyan Dong, Binyan Zhao, Li Yang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-16 (2023)
Abstract Despite the remarkable success of immune checkpoint inhibitors (ICIs), primary resistance to ICIs causes only subsets of patients to achieve durable responses due to the complex tumor microenvironment (TME). Oncolytic viruses (OVs) can overc
Externí odkaz:
https://doaj.org/article/10dadbfdfbf74015a5e1da6de591189d
Publikováno v:
World Electric Vehicle Journal, Vol 15, Iss 8, p 370 (2024)
In this paper, a time-varying delay output feedback control method based on the potential barrier function is proposed, which can solve the communication delay and field-of-view (FOV) constraints of Unmanned Ground Vehicle (UGV) clusters when communi
Externí odkaz:
https://doaj.org/article/cf5c4b0350e44d26b0be175f73c9c939
Autor:
Liren Li, Xingang Yao, Wenyu Wu, Shuwen Liu, Jiawen Zhang, Xiaoguang Chen, Yuanda Wan, Yihong Wan
Publikováno v:
Pharmacological Research. 170:105721
Dengue virus (DENV) is the most prevalent arthropod-borne viral disease of humans and has a major impact on global public health. There is no clinically approved drugs for DENV infection. Since intracellular VEGFR2 is increased in DENV infected patie
Publikováno v:
MedComm – Future Medicine, Vol 2, Iss 4, Pp n/a-n/a (2023)
Abstract Glioma is a common primary central nervous system malignant tumor in clinical, traditional methods such as surgery and chemoradiotherapy are not effective in treatment. Therefore, more effective treatments need to be found. Oncolytic viruses
Externí odkaz:
https://doaj.org/article/01817dd9511b4f8cb0dabc6e1133ad02
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Antimicrobial peptides are present ubiquitously in intra- and extra-biological environments and display considerable antibacterial and antifungal activities. Clinically, it has shown good antibacterial effect in the treatment of diabetic foot and its
Externí odkaz:
https://doaj.org/article/3e9ab40b21c548e097e5399f4feae926
Publikováno v:
MedComm – Oncology, Vol 2, Iss 1, Pp n/a-n/a (2023)
Abstract Treatment with immune checkpoint inhibitors (ICIs) has recently achieved unprecedented clinical benefits, becoming a critical treatment for patients with cancer. However, a set of patients are resistant to immune checkpoint inhibitor therapy
Externí odkaz:
https://doaj.org/article/263c143a90ec45249e117296f3d20793